	US 12,188,947 B2
	Marker for diagnosing atherosclerosis severity, and diagnostic method using same
Goo Taeg Oh, Seoul (KR); Sejin Jeon, Seoul (KR); Tae Kyeong Kim, Seoul (KR); Yangsoo Jang, Seoul (KR); Sung-Jin Hong, Seoul (KR); and Hye-Young Yun, Seoul (KR)
Assigned to EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION, Seoul (KR)
Appl. No. 17/293,946
Filed by EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION, Seoul (KR)
PCT Filed Nov. 5, 2019, PCT No. PCT/KR2019/014931 § 371(c)(1), (2) Date May 14, 2021, PCT Pub. No. WO2020/101251, PCT Pub. Date May 22, 2020.
Claims priority of application No. 10-2018-0140320 (KR), filed on Nov. 14, 2018; and application No. 10-2019-0140180 (KR), filed on Nov. 5, 2019.
Prior Publication US 2022/0026443 A1, Jan. 27, 2022
Int. Cl. G01N 33/68 (2006.01); A61K 38/17 (2006.01); A61P 9/10 (2006.01)

CPC G01N 33/6893 (2013.01) [A61K 38/1709 (2013.01); A61P 9/10 (2018.01); G01N 2800/2871 (2013.01); G01N 2800/323 (2013.01); G01N 2800/324 (2013.01); G01N 2800/56 (2013.01)]

6 Claims

1. A method for reducing plaque formation in a subject in need thereof, comprising the steps of:

(a) measuring the expression of leucine rich repeat LGI3 family member 3 (LGI3) comprising the amino acid sequence of SEQ ID NO: 1 in a subject sample comprising tissue, blood, serum, plasma, urine or saliva;

(b) diagnosing the subject as having severe arteriosclerosis, wherein an increase in expression of LGI3 comprising the amino acid sequence of SEQ ID NO:1 in comparison to the expression of LGI3 in a control group diagnoses the subject with severe arteriosclerosis, and wherein the average LGI3 expression of the control group is 4.34 ng/mL or less in a sample comprising tissue, blood, serum, plasma, urine, or saliva; and

(c) administering to the subject with severe arteriosclerosis a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of DEGRQKFVRFQELAV (SEQ ID NO:3).